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Rationale 
Recent studies report a possible mortality benefit of treatment with long-acting muscarinic 
antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA 
combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 
moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality 
with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-
to-severe COPD and a predominantly lower exacerbation risk. 
Methods 
Data were pooled from patients who participated in six phase 3/4 randomized controlled trials 
(TONADO 1/2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) and received treatment with either 
LAMA/LABA/ICS (n=11,891) or LAMA+LABA (n=3,156). There was no withdrawal of prior treatment 
at randomization in either arm, and the LAMA/LABA/ICS group were receiving ICS prior to study 
entry. The analysis was on-treatment and all data were censored at 52 weeks. To address any 
imbalance in characteristics between treatment arms, analyses were performed in a propensity 
score (PS)-matched cohort with age, sex, geographical region, smoking status, post-bronchodilator 
forced expiratory volume in 1 second (FEV1) percent predicted, exacerbation history, body mass 
index and time since diagnosis as covariates. Patients were PS-matched to those who received 
LAMA+LABA during the treatment period and had not previously received ICS. Cox proportional 
hazard regression models adjusting for covariates (see Figure) were used to assess time to all-cause 
mortality.  
Results 
After propensity score matching, there were 3,133 patients in both the LAMA+LABA and 
LAMA/LABA/ICS treatment groups. Baseline characteristics and comorbidities were well balanced 
between groups (LAMA+LABA vs. LAMA/LABA/ICS: male: 71.7% vs. 71.3%; age, mean±SD: 65.5±8.8 
years vs. 65.8±8.6 years; FEV1% predicted, mean±SD: 48.6±13.2% vs. 48.4±13.5%). Groups were 
composed mostly of infrequent exacerbators (patients with ≥2 COPD exacerbation in prior year: 
24.7% vs. 25.4%). Overall, there were 41 (1.3%) deaths in the LAMA+LABA group and 48 (1.5%) in 
the LAMA/LABA/ICS group. No significant difference in the time to death was observed between 
treatment groups (Figure; hazard ratio 0.93; 95% confidence intervals 0.60, 1.43; P=0.742). 
Sensitivity analyses using three additional models with different covariates showed similar results 
(Figure).  
Conclusions 
This pooled analysis of over 6,000 PS-matched patients showed no differences in mortality between 
LAMA+LABA and triple therapy in patients with moderate-to-very severe COPD and predominantly 




Figure. Time to all-cause mortality over 52 weeks for patients treated with LAMA+LABA versus 
LAMA/LABA/ICS 
 
 
 
